Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib
Crossref DOI link: https://doi.org/10.1007/s10067-016-3359-x
Published Online: 2016-07-28
Published Print: 2017-03
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Curtis, Jeffrey R.
Zhang, Richard
Krishnaswami, Sriram
Anisfeld, Andrew
Chen, Yan
Strengholt, Sander
Chen, Connie
Geier, Jamie
Funding for this research was provided by:
Pfizer
License valid from 2016-07-28